Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring showed similar physical, emotional, and psychological outcomes as those who received immediate treatment, based on the COMET clinical trial presented at the San Antonio Breast Cancer Symposium. Active monitoring involved close monitoring with surgery only if cancer developed. Nearly 995 patients were included, with half receiving active monitoring and half receiving standard care. Quality of life, anxiety, and worry about DCIS did not differ significantly between the two groups. While physical function scores differed slightly, the overall impact on quality of life was minimal. These findings suggest that active monitoring could be a viable option for low-risk DCIS patients.
Source link
Active monitoring for low-risk DCIS results in similar quality of life as standard treatment
